A practical reference on deamidation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-10 and is reviewed periodically as new material appears.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
肽类的主要降解路径包括天冬酰胺脱酰胺、甲硫氨酸氧化、天冬氨酸异构化以及由 β-折叠驱动的聚集，这些反应对 pH 与缓冲液种类较为敏感。磷酸盐、丙二醇与苯酚等辅料会影响局部微环境与界面行为。强制降解研究借助高温、强光、氧化剂与极端 pH 暴露来预测产物谱。关于长期室温存放的数据相对有限，超出标签条件的稳定性仍属开放问题，需要在具体制剂中通过实时与加速试验加以确认。
容器与密封系统同样参与稳定性表现。硅油涂层、胶塞材质与顶空氧含量可能改变聚集速率与氧化水平。分析结果因此需要在完整包装形式下评估，而不能仅凭原料药数据推断。法规文件通常要求同时提交批次数据与代表性容器中的稳定性趋势。
关于降解产物的免疫原性风险，文献中仍有讨论空间。体外聚集水平与临床免疫反应之间的定量关系尚未确立。多数公开研究只报告理化指标，缺少长期随访的对应数据。这一问题在生物类似物比对中尤其受到关注。
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
The earliest-known synapsid satisfying Kemp's definitions is Tikitherium, dated 225 Ma, so the appearance of mammals in this broader sense can be given this Late Triassic date. However, this animal may have actually evolved during the Neogene.
One of the important factors in determining the dentinal bonding is collagen. When dentin is etched, smear layer and minerals from dentinal structure will be removed, hence exposing the collagen fibres. The areas where the minerals are removed are filled with water which functions as plasticizer for collagen and keeps it at expanded soft state. This means that the spaces for resin-dentin bonding are preserved. However, these collagen fibres can collapse in dry condition and if the organic layer of matrix is denatured, this will obstruct the resin to bond with dentin and form a hybrid layer. Because of this, the presence of moist or wet dentin is required to achieve successful dentin bonding. This is due to presence of water miscible organic solvents like ethanol or acetone in the primers. The acetone trails water and hence improves the penetration of the monomers into the dentin for better micromechanical bonding. Also, water will prevent collagen fibres from collapsing, thus making better penetration and bonding between resin and dentin.
In cellular biology, reticular connective tissue is a type of connective tissue with a network of reticular fibers, made of type III collagen (reticulum = net or network). Reticular fibers are not unique to reticular connective tissue, but only in this tissue type are they dominant. Reticular fibers are synthesized by special fibroblasts called reticular cells. The fibers are thin branching structures.
Its initial contribution to LLFP radiation should be only about one part in 10000 for 235U fission, or 2000 for 65% 235U+35% 239Pu. Palladium is a noble metal and extremely inert. Iodine-129 has the longest half-life, 15.7 million years, and due to its higher half-life, lower fission fraction and decay energy it produces only about 1% the intensity of radioactivity as 99Tc. However, radioactive iodine is a disproportionate biohazard because the thyroid gland concentrates iodine. 129I has a half-life nearly a billion times as long as its more hazardous sister isotope 131I; therefore, with a shorter half-life and a higher decay energy, 131I is approximately a billion times more radioactive than the longer-lived 129I.
Georgia joined the Iraq war as part of the United States-led coalition in August 2003. By 2008, Georgia had deployed 2,300 troops in Iraq, becoming the third largest contributor to the coalition forces in the Iraq War. In addition, the country provided a battalion of approximately 550 troops to the United Nations Assistance Mission in Iraq. All Georgian troops were withdrawn from Iraq amid the Russia–Georgia war in August 2008. Georgia suffered five fatal casualties in Iraq.
Sources: en.wikipedia.org
===== Cetacean research ===== Peacock & Thewissen (2026) compare volume measurements of the bony labyrinth in extant mammals and Eocene cetaceans, and hypothesize that fossil cetaceans had membranous ducts of relatively larger size compared to terrestrial even-toed ungulates, and that vestibular organs of early cetaceans were necessary for terrestrial locomotion. Buono et al. (2026) reconstruct changes of cetacean morphological diversity and ecospace occupancy throughout the evolutionary history of the group, identifying Eocene–Oligocene and Plio–Pleistocene transitions as periods of major evolutionary changes, and linking changes of ecospace occupancy to the main radiation events of the group. Tyborowski et al. (2026) report the discovery of a portion of a dentary of an indeterminate member of Pelagiceti from the Siemień Formation, representing the first record of an Eocene whale from Poland and one of the smallest fully aquatic Eocene whales reported to date. A deciduous tooth of a basilosaurid with evidence of malformation that might have been caused by localized stress is described from the Eocene Submeseta Formation (Seymour Island, Antarctica) by Bajor et al. (2026). Hakkens, Reumer & Schulp (2026) study the affinities of the basilosaurid specimen TM 8501 from the Eocene (Priabonian) Yazoo Clay (Alabama, United States; the holotype of Zeuglodon hydrarchus), identify the studied individual as a mid-sized cetacean distinct from Dorudon serratus and Chrysocetus healyorum, an tentatively refer the specimen to Zygorhiza kochii. Davydenko et al.
Many different studies have been conducted on the sensory changes that occur in wines that have gone through malolactic fermentation. The most common descriptor is that acidity in the wine feels "softer" due to the change of the "harsher" malic acid to the softer lactic acid. The perception of sourness comes from the titratable acidity in the wine, so the reduction in TA that follows MLF leads to a reduction in perceived sour or "tartness" in the wine. The change in mouthfeel is related to the increase in pH, but may also be due to the production of polyols, particularly the sugar alcohols erythritol and glycerol. Another factor that may enhance the mouthfeel of wines that have gone through malolactic fermentation is the presence of ethyl lactate which can be as high as 110 mg/L after MLF. The potential influence on the aroma of the wine is more complex and difficult to predict with different strains of Oenococcus oeni (the bacterium most commonly used in MLF) having the potential to create different aroma compounds. In Chardonnay, wines that have gone through MLF are often described as having "hazelnut" and "dried fruit" notes, as well as the aroma of freshly baked bread. In red wines, some strains metabolize the amino acid methionine into a derivative of propionic acid that tends to produce roasted aroma and chocolate notes. Red wines that go through malolactic fermentation in the barrel can have enhanced spice or smoke aromas.
== History == In 2003, Lifeline Therapeutics, a privately held Denver-based nutraceutical licensing and marketing company, entered into an agreement with Massachusetts biotechnology company CereMedix for the rights to market CMX-1152, an experimental peptide-based compound, under the brand name "Protandim" (also sometimes referred to at that time as "Rholen," "Rejuven8r" and "ependymin"). CereMedix was a ten percent owner of Lifeline and members of the CereMedix management board served on Lifeline's board of directors. CMX-1152 was claimed to upregulate the production of the endogenous antioxidant enzymes superoxide dismutase, catalase, and glutathione peroxidase, and to offset the aging process. CMX-1152 was due to be marketed as an over the counter anti-aging pill in June 2004 after completing human clinical trials. However, plans to market the CMX-1152 version of Protandim fell through and in April 2004 Lifeline Therapeutics announced that it would instead be marketing a different (non-peptide) dietary supplement under the name "Protandim CF" (to distinguish it from the peptide version initially developed by Cermedix). The new version of Protandim, a combination of five common herbal ingredients including turmeric and green tea was invented following "months of extensive research and development" by Lifeline employees Paul Myhill and William Driscoll (a former oil company executive), who together hold the patent on the product, and it was launched in February 2005. Myhill and Driscoll resigned from the company later that year.
On the second issue, CAS stated they could not "permit an athlete to establish how a substance came to be present in his body by little more a denial that he took it", that there was "nothing more than speculation, unsupported by any evidence of any kind", that Elsalam did not substantiate her hypothesis with any evidence aside from the receipt presented, that little attempt was made "to establish the causal link" and that it was "noteworthy" that Elsalam had not "produced a single piece of evidence demonstrating or even substantiating that other consumers (including athletes) having purchased and eating [sic] meat in Egypt within the relevant time have been subjected to food contamination with [ractopamine]" CAS upheld WADA's appeal, ruling a violation was committed, and that Elsalam had not met her burden of proof, so the violation "must be deemed to have been intentional". It was explicitly stated that they had "not pronounced the Athlete as a 'cheater'". Elsalam's ineligibility period was extended to four years. In October 2017 at a WADA conference, it was suggested in relation with ractopamine:
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.